The FDA clearance opens the door to the world's largest medical device market. With the cost effectiveness and demonstrated ability of our cardiac monitori...
The earnings release and accompanying financial information will be posted on the IQVIA Investor Relations website at http://ir.iqvia.com. To listen to th...
Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the q...
Agilent Technologies Inc. (NYSE: A) announced the latest addition to the Cary 3500 UV-Vis Series with the release of the Agilent Cary 3500 Flexible U...
The project will see the site’s footprint increase by 32,000 square feet (3,000 square meters) to add capacity for the storage and handling of clinic...
Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the de...
he Phase 1, first-in-human, multicenter clinical study seeks to characterize the safety, potential efficacy and evaluate possible biomarkers of response to...
One promising approach involves delivering antiviral compounds vaginally, using inserts, gels, films, or intravaginal rings. This method is appealing becau...
Xylyx Bio, a regenerative medicine company developing breakthrough technologies for organ and tissue repair, today announced findings from an independent c...
Synapse Biomedical, Inc. announced today that the FDA has granted premarket approval (PMA) of the NeuRx® Diaphragm Pacing System (NeuRx DPS®) for u...
Accord BioPharma, the U.S. specialty division of Intas Pharmaceuticals, Ltd., focused on development of oncology, immunology, and critical care therapies, ...
Jingsong Wang, MD, PhD, Chairman of Nona Biosciences, said, " By combining our respective expertise in antibody engineering and the disease area, we a...
WuXi STA, a global Contract Research, Development, and Manufacturing Organization (CRDMO), announces that it has added two 2,000 L reactors and a large-sca...
Interim report of the safety and immunogenicity endpoints from the Phase II/III study has been submitted to the Drug Controller General of India (DCGI) f...
© 2025 Biopharma Boardroom. All Rights Reserved.
